key: cord-0946628-fdfnzvnz
authors: Ahmad, Faisal; Albutti, Aqel; Tariq, Muhammad Hamza; Din, Ghufranud; Tahir ul Qamar, Muhammad; Ahmad, Sajjad
title: Discovery of Potential Antiviral Compounds against Hendra Virus by Targeting Its Receptor-Binding Protein (G) Using Computational Approaches
date: 2022-01-16
journal: Molecules
DOI: 10.3390/molecules27020554
sha: 5708b10fba9f95ea875bd04afe56c278fc2cc34e
doc_id: 946628
cord_uid: fdfnzvnz

Hendra virus (HeV) belongs to the paramyxoviridae family of viruses which is associated with the respiratory distress, neurological illness, and potential fatality of the affected individuals. So far, no competitive approved therapeutic substance is available for HeV. For that reason, the current research work was conducted to propose some novel compounds, by adopting a Computer Aided Drug Discovery approach, which could be used to combat HeV. The G attachment Glycoprotein (Ggp) of HeV was selected to achieve the primary objective of this study, as this protein makes the entry of HeV possible in the host cells. Briefly, a library of 6000 antiviral compounds was screened for potential drug-like properties, followed by the molecular docking of short-listed compounds with the Protein Data Bank (PDB) structure of Ggp. Docked complexes of top two hits, having maximum binding affinities with the active sites of Ggp, were further considered for molecular dynamic simulations of 200 ns to elucidate the results of molecular docking analysis. MD simulations and Molecular Mechanics Energies combined with the Generalized Born and Surface Area (MMGBSA) or Poisson–Boltzmann and Surface Area (MMPBSA) revealed that both docked complexes are stable in nature. Furthermore, the same methodology was used between lead compounds and HeV Ggp in complex with its functional receptor in human, Ephrin-B2. Surprisingly, no major differences were found in the results, which demonstrates that our identified compounds can also perform their action even when the Ggp is attached to the Ephrin-B2 ligand. Therefore, in light of all of these results, we strongly suggest that compounds (S)-5-(benzylcarbamoyl)-1-(2-(4-methyl-2-phenylpiperazin-1-yl)-2-oxoethyl)-6-oxo-3,6-dihydropyridin-1-ium-3-ide and 5-(cyclohexylcarbamoyl)-1-(2-((2-(3-fluorophenyl)-2-methylpropyl)amino)-2-oxoethyl)-6-oxo-3,6-dihydropyridin-1-ium-3-ide could be considered as potential therapeutic agents against HeV; however, further in vitro and in vivo experiments are required to validate this study.

A growing number of emerging viral diseases is due to the natural viral reservoirs in different animals such as bats [1] , and these zoonotic viruses are estimated to be responsible for 70% of infectious diseases [2] . One such pathogenic Zoonotic origin virus is Hendra of SARS-CoV-2 [16] . Similarly, Anasir et al. and Dash et al., designed therapeutic substances against the surface glycoprotein of Dengue virus [17] and Ebola virus [18] , respectively.

Recently, the use of bioinformatics tools has revolutionized the field of drug discovery, as with the aid of these computational methods, the therapeutic potential of a variety of substances of interest can be assessed against different diseases. This saves wet lab resources as well as time and finally proposes therapeutic substances with strong potential to act as a drug against the disease under consideration [19] . The proposed study also employed different computational approaches, such as virtual screening of chemical compounds, molecular docking, and molecular dynamics simulation analysis, to identify the "best hits" that will serve as a baseline for the pharmaceutical industry to combat HeV.

The G attachment glycoprotein (Ggp) of HeV was selected to identify the potential inhibitors of HeV. To begin the research work, the three-dimensional structure of Ggp in complex with human Ephrin-B2 receptors was retrieved from the protein data bank (PDB) [20] , under PDB ID: 2VSK. This structure was used in two distinct ways for further analysis; one in the native complex form and the other one in discrete Ggp form. The intact Ggp structure was separated from the docked complex through Discovery Studio 3 .5v 2019 Vélizy-Villacoublay FRANCE [21] . The purpose of considering both the un-bounded and bounded Ggp structure was to identify the effect of inhibitors on Ggp in two different scenarios; when the virus exists in intact form and when the virus is attached to the host cellular receptors. In order to improve the quality of the selected models of the target proteins, energy minimization was done through UCSF Chimera 1.15v 2020 University of California USA. This software is also a powerful visualization software; hence, it was also considered to analyze the final prepared structures [22] .

Potential inhibitors against the target were gathered using the Asinex BioDesign database (http://www.asinex.com) antiviral library, on 22 July 2021. This library of small chemicals was further used in structure-based virtual screening. Prior to that, the library was screened for drug-like inhibitors first, followed by screening for lead-like inhibitors using the Swiss-ADME online tool (http://www.swissadme.ch/) on 23 July 2021 [23] . Firstly, investigations were made to check whether the compounds present in the library violated drug-like rules, namely, the Lipinski rule of five, Muegge rule, Egan rule, and Veber rule, each of which evaluates drug-like properties based on distinct parameters [24] [25] [26] [27] . Additionally, different medicinal chemistry parameters, Pan Assay Interference (PAINS), Synthetic accessibility, and Brenk Alert, were also considered to short-list the compounds [28] [29] [30] . Compounds with no PAINS substructure, high synthetic accessibility, and minimum Brenk Alert were eventually considered to be the lead compounds. Compounds following all of the above-mentioned rules were further screened for Adsorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET)-related properties [31] . Both HIA and BBB were estimated using a BOILED-EGG plot [32] . This plot examines the TPSA and LogP of the compound under consideration and predicts its pharmacokinetics with respect to BBB and HIA [32] . Another important parameter considered while estimating pharmacokinetics is solubility in water, as high solubility means even a small volume of the drug is sufficient for absorption within the body [33] . Moreover, Immunogenecity, Mutagenecity, AMES toxicity, and Pro-ToxII tests predictions were carried out to estimate the toxicity of the short-listed compounds.

Finally, a comparison between the drug-likeliness and non-drug-likeliness of the lead compounds was done through the molsoft online tool (http://molsoft.com/) on 25 July 2021, whose working is based on different physiochemical properties, including the molecular weight, number of HBDs, number of HBAs, MolLogP, MolLogS, MolPSA, MolVol, number of stereo centers, BBB score, and pKa of acidic and basic groups [34] . A total of 6000 compounds were isolated from the library after applying the aforementioned filters, with 3560 lead-like compounds being chosen for further study. Compounds with acceptable lead-likeness capabilities were then separated from the other compounds. The energy of these potent inhibitors was then minimized using the MMFF94 force field using Discovery Studio 2017.

Active site identification, ligand preparation, and molecular docking were the three main stages in the molecular docking approach. From a literature point of view, the active pocket residues reside among the loop region Glu119-Trp125 and other essential binding residues, i.e., Tyr255, Asp219 Tyr305, Lys357, Tyr508, Gln559, Tyr581, and Gln 579, that catalyze the hydrolysis of the alpha-(2->3)-, alpha-(2->6)-, alpha-(2->8)-glycosidic linkages of terminal sialic residues in oligosaccharides and glycoproteins [1] . The active cavity in the protein three-dimensional structure of molecule binding must be investigated for effective suppression. Appropriate active sites are classified according to their buriedness, size, shape, and hydrophobic considerations [35] . The active site for (PDB-2VSK) was identified from the literature review and was confirmed manually via sequence alignment of our target sequence. The active site residue confirmed during physical examinations was similar in comparison to the one reported in the literature.

Then, molecular docking was performed following the same protocol published in our previous studies [36] [37] [38] between 3560 lead-like compounds with the un-bounded structure of Ggp by using AutoDock Vina v.1.2.0 software CCSB California USA, whose working is based on the protocols of Genetic Optimization [39] . The best ligands against the target protein were classified based on their binding affinities. To visualize the docked protein complexes and the interactions that lead to ligand binding in detail, UCSF Chimera [21] and Visual Discovery studio (DS) [21] were applied. The top ten compounds were then docked against the complex of Ggp and Ephrin-B2 receptors to check their binding affinity with the bounded form of Ggp.

MD simulations were used to investigate the behavior of docked proteins using an explicit water molecules (TIP3P) water box with a size dimension of 8.0 Å having Na + or Cl − , according to the solute charge to neutralize the system. During the system preparation, the protein was assembled using the pdb4amber tool, where its protonation state and missing residues were adjusted. Assisted Model Building with Energy Refinement (AMBER 16) software (University of California, San Francisco) was used, and several modules were applied for analysis [40] . The initial coordinates and topological files were generated using the TLeap package of (AMBER 16) software. The facility was built using the ff14SB force field. A constant temperature was achieved using the Berendsen Coupling Integration Algorithm. The Process TRAJectory (PTRAJ) module of (AMBER 16) was used to conduct the outcomes analysis. Xmgrace 5.1.25v University of Cambridge UK, was used to compute and visualize four attributes [41] . The same protocol was followed for MD simulations as published in our previous studies [36] [37] [38] 42] . The simulation time was extended to 200 ns, and the root mean square deviation (RMSD), root mean square fluctuation and (RMSF), radius of gyration (Rg), and B-factor analyses were performed.

The radial distribution function, g(r), for a group of N atoms is the probability of finding an atom in a spherical volume of radius r [43] . In the current study, RDFs between amino acids in the vicinity of the pocket and ligand were plotted to gain insight into conformational variations induced by intermolecular interactions. Radial distribution functions (RDFs) were extracted using PTRAJ in order to quantify the density of a specified atom around another definite atom at an ideal distance for interaction. The expression for the radial distribution function is presented in the Equation (1) .

(1)

In the above equation, ρij is the observed number density of one specified atom of the molecule (solvent) at a specified distance, (r), from one atom of the other molecule (solute). The function g(r) is the ratio between this observed number density ρij at the distance r and the average bulk atom number density of the solvent, ρj. This ratio is equal to the ratio between nij(r) and <ρj>4πr2∆r where nij is the bin number of atoms in a spherical volume fragment, dependent on the bin width ∆r. In other words, the RDF provides the probability of finding the one specified atom of the solute in a specified volume, at a distance (r) from another specified atom of the solvent. The factor 4πr2∆r gives the volume of a spherical shell with a thickness, ∆r, at a distance (r) from the chosen solute atom. The ratio between the number of solvent atoms found in this spherical volume (4πr2∆r) at a distance (r) from the specified solute atom and the bulk density of solvent atoms (again molecules) gives the probability of finding the solvent atom at this distance from the solute atom as compared to a solute atom in bulk solution, which is referred to as the g(r) value.

The MMPBSA method was used to calculate the binding free energies against an average of 1000 frames of MD simulations [44] by calculating the difference among the individual free energy of the ligand and receptors and both in a single complex entity (Equation (2)):

The ∆G in Equation (6) is Gibb's free energy that is calculated by MMGB/PBSA for each term as shown in Equation (3):

where T depicts temperature and S demonstrates the entropy contribution to ligand binding, which was predicted through identified approximations. E gas shows the gas phase energy, which in most of the cases, represents the MM energy from the force field. E gas basically covers contributions from both internal energy and van der Waals' interaction and electrostatic energies (Equation (4)):

Another important value is that of ∆G solv , which is estimated through an implicit solvent model. ∆G solv considers both non-polar and electrostatic contributions (Equation (5)):

Equation (5) is the addition of electrostatic energy and polar solvation components (Equation (6)):

∆G ele PB/GB = E ele + ∆GPB/GB

In Equation (6) , G np is the non-electrostatic contribution and is proportional to the solvent-accessible surface area of the molecule (Equation (7)), which is calculated through the LCPO (Linear Combinations of Pairwise Overlaps) method [44] in MMPBSA with a water probe radius of 1.4 Å.

The standard values for constants γ and β in Equation (7) were used in this analysis, which are 0.0072 kcal/mol·Å 2 and 0 kcal/mol, respectively, in MMGBSA and 0.0052 kcal/mol·Å 2 and 0.92 kcal/mol, respectively, in MMPBSA.

The WaterSwap technique from the Sire package2020.1.0 (University of Bristol), based on the explicit solvent model, was also ad used to further assess the binding free energies of our systems [45, 46] . The working of this technique involves the swapping of ligand dimensions with an equal volume and size of the binding site-explicit water molecules, making it possible to calculate the free energy contribution of the water molecules, which are contemporaneous with the binding pocket of Ggp. To perform the WaterSwap analysis, trajectories from the last 10 ns MD simulations were considered, and in total, 1000 iterations were conducted. Four distinct methods of binding free energy calculation were considered for the estimation of absolute binding free energy, namely, thermodynamic integration (TI), free energy perturbation (FEP), quadrature-based integration of TI, and Bennett's acceptance ratio (BAR) method. The final forecasted values of <1 kcal/mol were evaluated to be the ideal values, depicting the overall high stability in the studied complexes [47] .

The current study was aimed to identify the novel inhibitors of the Ggp of Hendra virus. For this purpose, a library of energy minimized 3560 antiviral compounds (http: //www.asinex.com/?page_id=17) (accessed on 7 January 2022) (with acceptable drug-like properties) was docked with the active sites of the Ggp in two forms; Ggp unbounded and Ggp bounded with Ephrin-B2. Once the molecular docking was completed, antiviral compounds were ranked based on four different parameters, i.e., minimum Gibbs free energy, maximum occupancy of the binding pocket, strength of hydrogen bonding, and other possible non-covalent contacts. The top five best docked compounds were the same in both studied scenarios; their chemical structures and Gibbs free energies are shown in Table 1 , which clearly indicates that these top five compounds had a free energy within the range of −9.7 kcal/mol and −7.4 kcal/mol. 

Among these top five compounds, the two top-most compounds had a Gibbs free energy considerably lower than the others; these two antiviral agents are Top1 [(S)-5-(benzylcarbamoyl)-1-(2-(4-methyl-2-phenylpiperazin-1-yl)-2-oxoethyl)-6-oxo-3,6-dihydropyridin-1-ium-3-ide] and Top2 [5- 

The docking poses and binding interactions of these best docked compounds with the active residues of Ggp are shown in Figure 1 .

Among these top five compounds, the two top-most compounds had a Gibbs free energy considerably lower than the others; these two antiviral agents are Top1 [(S)-5-(benzylcarbamoyl)-1-(2-(4-methyl-2-phenylpiperazin-1-yl)-2-oxoethyl)-6-oxo-3,6-dihydropyridin-1-ium-3-ide] and Top2 [5- 

The docking poses and binding interactions of these best docked compounds with the active residues of Ggp are shown in Figure 1 .

Among these top five compounds, the two top-most compounds had a Gibbs free energy considerably lower than the others; these two antiviral agents are Top1 [(S)-5-(benzylcarbamoyl)-1-(2-(4-methyl-2-phenylpiperazin-1-yl)-2-oxoethyl)-6-oxo-3,6-dihydropyridin-1-ium-3-ide] and Top2 [5- 

The docking poses and binding interactions of these best docked compounds with the active residues of Ggp are shown in Figure 1 . Among these top five compounds, the two top-most compounds had a Gibbs free energy considerably lower than the others; these two antiviral agents are Top1 [(S)-5-

The docking poses and binding interactions of these best docked compounds with the active residues of Ggp are shown in Figure 1 .

All of the selected compounds, which were used for docking analysis, were previously validated for acceptable drug-like properties. Table 2 shows the physiochemical properties of the top two hits, which were evaluated by different rules of drug-likeliness. This table also states that these compounds have zero violation for all the commonly considered rules of drug-likeliness, i.e., Lipinski rule of 5, Veber rule, Muegge rule, and Egan rule. Furthermore, they also showed acceptable characteristics of medicinal chemistry, including Pan-assay interference compounds (PAINS), structure alert (brenk), and synthetic accessibility. The top two compounds also demonstrated normal parameters of Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET).

The BOILED-EGG plot is illustrated in Figure S1 , according to which the analyzed compounds lie within the white region of the egg, depicting strong human intestinal absorption and incapability of crossing the blood-brain barrier, which is again a strongly desirable characteristic of a potential therapeutic substance. Likewise, other ADMETrelated properties were normal in both of the candidate inhibitors (Table S1) , with only 06 and 04 violations in the top 1 and top 2 hits, respectively. Finally, a comparison between the drug-like and non-drug-like properties was made through the molsoft online tool, the results of which also showed that the analyzed compounds had significantly more drug-like properties than non-drug-like ones ( Figure S2 ). All of the selected compounds, which were used for docking analysis, were previously validated for acceptable drug-like properties. Table 2 shows the physiochemical properties of the top two hits, which were evaluated by different rules of drug-likeliness. This table also states that these compounds have zero violation for all the commonly considered rules of drug-likeliness, i.e., Lipinski rule of 5, Veber rule, Muegge rule, and Egan rule. Furthermore, they also showed acceptable characteristics of medicinal chemistry, including Pan-assay interference compounds (PAINS), structure alert (brenk), and synthetic accessibility. The top two compounds also demonstrated normal parameters of Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET). The BOILED-EGG plot is illustrated in Figure S1 , according to which the analyzed compounds lie within the white region of the egg, depicting strong human intestinal absorption and incapability of crossing the blood-brain barrier, which is again a strongly 

The top two best categorized docked complexes were additionally considered for molecular dynamic simulations to validate the molecular docking results. MD simulations were performed for 200 ns, and the stability of the complex was estimated through different statistical parameters, i.e., root mean square fluctuation (RMSF), root mean square distribution (RMSD), beta-factor, and the radius of the gyration factor ( Figure 2 ). Throughout the 200 ns simulations, both studied compounds maintained their stability within the docked site of individual Ggp and Ggp in complex with Ephrin-B2; therefore, all four were contemplated for further exploration. The structural integrity of the protein-ligand complex was estimated by calculating the RMSD value of the backbone of the docked complex. The average RMSD value of docked complexes with native Ggp was found to be lower than their respective docked complexes with Ggp bounded to Ephrin-B2 receptors. The mean RMSD of the top compound (attached to unbounded Ggp) was 1.9 Å, while this value was 2.1 Å for its docked complex with Ggp in complex with Ephrin-B2, with a displacement of 0.25 Å. Similarly, the average RMSD value of the top 2 compound bounded to Ggp and Ggp previously complexed with Ephrin-B2 receptors was 1.7 Å and 2.5Å, respectively, displaying a displacement of 0.9 Å.

To estimate the residual flexibility of the backbone of unbounded compounds and docked complexes, the RMSF value was calculated. There were no major fluctuations in the assessed structures. The average RMSF value for the top 1 bounded with Ggp, top 1 docked complex with Ggp and Ephrin-B2, top 2 bounded with Ggp, and top 2 docked complex with Ggp and Ephrin-B2 was 3.8 Å, 3.3 Å, 2.3 Å, and 2.2 Å, respectively. Furthermore, Rg values were determined to estimate the compactness of the protein structure. The average Rg value for the top compound with Ggp was 23 Å 2 , which was 24 Å 2 for its docked complex with Ggp already attached to Ephrin-B2. A similar trend was seen for the top 2 compound, where the mean Rg value for the compound with Ggp alone was 23. Å 2 ; however, for Ggp attached to Ephrin-B2 in complex with the top 2 compound, this value was 24.8 Å 2 . To analyze the thermal disorders and additional residual flexibility, the beta factor was calculated. The mean values of the beta factor for the top 1 and top 2 compound, docked with Ggp, were 99 Å 2 and 78 Å 2 , respectively, while the respective values were 81 Å 2 and 75 Å 2 for the receptor protein in complex with the Ephrin-B2 receptors. The stability of both inhibitors was inferred with a time frame of 200 ns. It was calculated that both inhibitors remained in pockets with no confirmatory changes and angular displacement. Thus, the average mean square deviation had a score of 1.3 Å for Top1 and 1.3 Å for Top2, respectively. Moreover, the RMSD for the single Ggp and Ggp in complex with Ephrin-B2 was calculated. The average root mean value for Ggp was 4.5 Å and 1.3 Å in complex with Ephrine-B2. In the meanwhile, average root mean square deviation of both inhibitors have been obtained, results shows a high stability with average RMSD of 1.5 Å for Top1 and 1.6 Å for Top2 inhibitor throughout simulations. Whereas, average RMSD calculated against single Ggp protein results in 4.8 Å, while in complex with Ephrin-B2 it has an average RMSD of 1.8 Å which make them stable along 200 ns time interval as shown in (Figure 3 ). The stability and strength of hydrogen bonds, which were previously represented in Figure 1 , were also analyzed during MD simulations, as their stability is directly associ- 

RDF analysis was performed to elucidate the distribution of atoms around the binding sites of the target protein. An in-house script in VMD was employed to point out the important residues of the target protein that can play an essential role in establishing hydrogen bonds with the ligand throughout the MD simulations. The RDF graphs were generated at both 1 ns and 200 ns to confirm whether the residues remained active throughout the simulations. Figure 5 depicts that in the complex of the top 1 inhibitor and Ggp+ Ephrin-B2, Tyr 255 and Lys 357 were the most vital residues of Ggp in forming the hydrogen bonds. Tyr 255 had an RDF value far higher than that of Lys 357 at both times, with an RDF value of 4.9 at 1 ns and 4.1 at 200 ns. This distribution was observed between the HH atom of Tyr 255 and the 19th oxygen of the top 1 compound, at a distance of 1.75 Å. The RDF plot of the Ggp+ Ephrin-B2 protein in complex with the top 2 compound represented that same residue involved in forming bonds with the ligand, i.e., Lys 357 and Tyr 255. However, at this time, Tyr 255 had a very high RDF value (2.5) at 200 ns compared to 1 ns (0.75). Distribution due to Tyr 255 was due to its HH atom and the 18th oxygen atom of the top 2 compound. Lys357 showed relatively different behavior; two different RDFs were seen at two different distances in the 1 ns and 200 ns simulations. During the simulation of 1 ns, an RDF of 0.75 was seen at a 1.75 Å distance followed by many fluctuating peaks with the last major peak at a 3.2 Å distance and a 0.6 RDF value. Similarly, in the 200 ns time frame, the first peak was visualized at a distance of 1.75 Å (RDF = 1.2) with an immediate fluctuation at 1.85 Å (1.1). Additionally, one more major peak was found at 3.3 Å (RDF = 0.75) followed by another instant peak at 3.45 Å (RDF = 0.5). All of these distributions were observed between the HZ1 residue of protein and the 18th oxygen of the ligand. For the docked complex of the top 1 compound and Ggp alone, only Tyr255 was found to be involved in hydrogen bonding with the inhibitor. This hydrogen bond represented an RDF value of 1.25 at 1 ns and 0.8 at 200 ns at a distance of around 0.8 Å and 0.77 Å, respectively. The HH atom of Tyr 255 and the 14th oxygen of the top 1 hit were reported to be responsible for this distribution. For the docked complex of the top 2 compound and Ggp protein alone, three different residues of Ggp were assessed to be responsible for hydrogen bonds, i.e., Tyr255, Thr304, and Tyr305. At 1 ns the RDF for these residues was 1.85 (2 Å), 1.3 (1.9 Å), and 0.65 (2.1 Å) respectively. However, there were so many fluctuations until 200 ns as seen in (Figure 5 ). For Tyr255, HH atoms and the 19th oxygen of the top 2 hit formed steady hydrogen bonds, and the same oxygen atom was identified to form hydrogen bonds with the H atom of tyr305. For Thr 304, the HG1 atom exhibited hydrogen bonding with the 18th oxygen atom of the ligand. Good stability was seen in all of these bonds at 200 ns with an RDF value of 0.85 (4.1 Å) for Tyr255 and 0.25 (at both 1.4 Å and 4.15 Å distance) for Thr304. For Tyr305, the RDF value was found to be 0.35 at 4.1 Å; however, this value was calculated at 100 ns as after that, this bond did not remain stable. 

The binding free energies of both the top 1 and top 2 inhibitors in the active sites of Ggp and Ggp+ Ephrin-B2 are shown in Table 3 . The free energy in the gas phase was the most favorable energy in both GB and PB, which was found in 

The binding free energies of both the top 1 and top 2 inhibitors in the active sites of Ggp and Ggp+ Ephrin-B2 are shown in Table 3 . The free energy in the gas phase was the most favorable energy in both GB and PB, which was found in 

Water is considered an important solvent as its molecules serve as the interactive bridges between the protein and its inhibitor (ligand). Therefore, in the current experimental work, the explicit water model of WaterSwap was used to investigate the molecular details of ligand-water, protein-water, and protein interactions. Table 4 represents the free binding energy calculated using four different algorithms in WaterSwap analysis. The results show that the binding potential of all studied complexes was lower than 1 kcal/mol, which is acceptable as the standard value is <1 kcal/mol. 

HeV is one of the deadliest known viruses for humans with no approved therapeutic substance; therefore, we conducted this research work to propose lead compounds that could be used as future anti-HeV drugs. For this purpose, extensive CADD-based computational methods were adopted.

Firstly, the database of 6000 anti-viral compounds was screened for pharamcokineticsbased parameters, as used by many researchers in previously published studies [48] [49] [50] . Compounds having acceptable drug-like properties were considered for molecular docking analysis against Ggp of HeV through Autodock Vina software. This software has been used extensively to perform molecular docking analysis to propose potent inhibitors of deadly viruses [51] [52] [53] . The docking study revealed that compounds (S)-5-(benzylcarbamoyl)-1-(2-(4-methyl-2-phenylpiperazin-1-yl)-2-oxoethyl)-6-oxo-3,6-dihydropyridin-1-ium-3-ide and 5-(cyclohexylcarbamoyl)-1-(2-((2-(3-fluorophenyl)-2-methylpropyl)amino)-2-oxoethyl)-6-oxo-3,6-dihydropyridin-1-ium-3-ide had the maximum binding potential with the active residues of Ggp in both unbounded and bounded form. Hydrogen bonds formed by them not only assist in filtering the unrealistic poses in docking but also help in precise calculation of the binding energy [54] . Developed hydrogen bonds were found to be stable in MD simulation studies, which are considered an effective methodology to validate the results of molecular docking analysis, as shown in many previous studies [55] [56] [57] . Furthermore, the stability of the entire system was confirmed through RDF analysis. MMGBSA/MMPBSA was employed to evaluate the binding free energies, which in turn explains the strength of binding affinities between inhibitors and proteins [58] . The MMGBSA/MMPBSA method is well demonstrated in binding free estimation for antiviral inhibitors [38, 59, 60] . Data from this step indicated that the bounded ligand will not be easily displaced by the solvents and hence, the stability of docked complex will be sustained [59] .

A major limitation in MMGBSA and MMPBSA is the creation of cavitation and great differences during double decoupling. To overcome this shortcoming, WaterSwap analysis was conducted to elucidate the stability of the docked complex to measure the absolute values of the binding free energy [46] . WaterSwap assessment indicated that the binding affinity of the studied complexes was higher than the standardized value of <1 kcal/mol. Many scientists have used the same methodology to forecast potential therapeutic compounds against different viruses such as SARS-CoV-2 [60] , Dengue virus [61] , and Nipah virus [62] . Therefore, CADD-based drug discovery appears to be capable of combating pathogens including viruses.

To the best of our knowledge, this is the first study to suggest antiviral compounds as the potential drugs against HeV. Although a subunit vaccine is under clinical trials in human [63] and immunoinformatics-based silico vaccines have recently been proposed by Kamthania et al., and Hossan et. al. [64, 65] , no anti-HeV oral drug has been reported or proposed before. Ribavirin and Chloroquine are the two anti-viral drugs that have been tested for their anti-HeV activity. Chloroquine (an anti-malarial drug) acts by inhibiting the critical proteolytic processing of HeV, whereas Ribavirin inhibits the replication of HeV [1, 4] . Both of these drugs only delay the HeV infection; they do not eradicate the chances of virus-mediated death [66] . In contrast to this, our proposed compounds have a strong potential to inhibit the G glycoprotein, which makes the attachment of the virus possible with human receptors. Therefore, the current study indicates huge potential for drug discovery against HeV.

HeV infection is a global health issue that results in many neurological disorders. Due to the unavailability of any approved therapeutic option, it is necessary to identify some therapeutic methods to combat this harmful viral infection. Because of the enormous advantages, computer-aided drug discovery was employed to propose the lead compound against HeV. Our study proposed that (S)-5-(benzylcarbamoyl)-1-(2-(4-methyl-2-phenylpiperazin-1yl)-2-oxoethyl)-6-oxo-3,6-dihydropyridin-1-ium-3-ide and 5-(cyclohexylcarbamoyl)-1-(2-((2-(3-fluorophenyl)-2-methylpropyl)amino)-2-oxoethyl)-6-oxo-3,6-dihydropyridin-1-ium-3-ide are the lead compounds with maximum binding affinity with the active sites of the G glycoprotein of HeV, even if HeV is attached to its human cellular receptors, thereby, inhibiting its pathogenesis. Further wet laboratory investigations are necessary to authorize the safety and efficiency of these lead compounds against HeV.

Supplementary Materials: The following supporting information can be downloaded online. Figure S1 : BOILED-Egg plot of the top two compounds with the best binding ability to the G glycoprotein of Hendra Virus, where molecule 1 and 2 code for the top 1 and top 2 compound in Table 1 , respectively. Figure S2 : Comparison of drug-like and non-drug-like properties of the top 1 (a) and top 2 (b) drug candidates. Table S1 : Different parameters of ADMET properties upon which ADMETsar evaluates the pharmacokinetics properties of a compound. Normal properties are not highlighted while those that deviate from the normal range are highlighted in red.

Hendra and Nipah viruses: Different and dangerous

Global trends in emerging infectious diseases

Origin and evolution of Nipah virus

The exceptionally large genome of Hendra virus: Support for creation of a new genus within the family Paramyxoviridae

Molecular characterization of the polymerase gene and genomic termini of Nipah virus

Hendra and Nipah viruses: Why are they so deadly?

WHO's blueprint list of priority diseases

Hendra virus: Epidemiology dynamics in relation to climate change, diagnostic tests and control measures

Structure and organization of paramyxovirus particles

What is new in infectious diseases: Nipah virus, MERS-CoV and the blueprint list of the World Health Organization

Hendra virus disease: A highly infectious emerging anthropozoonosis

Pathology of acute henipavirus infection in humans and animals

Human Hendra virus encephalitis associated with equine outbreak

Structural basis of Nipah and Hendra virus attachment to their cell-surface receptor ephrin-B2

Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus

Computer-aided drug design against spike glycoprotein of SARS-CoV-2 to aid COVID-19 treatment

Structure-based design of antivirals against envelope glycoprotein of dengue virus

In silico-based vaccine design against Ebola virus glycoprotein

Accelerating drug discovery: Although the evolution of '-omics' methodologies is still in its infancy, both the pharmaceutical industry and patients could benefit from their implementation in the drug development process

Protein Data Bank (PDB): Database of threedimensional structural information of biological macromolecules

UCSF Chimera-A visualization system for exploratory research and analysis

SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

Using Multivariate Statistics

Molecular properties that influence the oral bioavailability of drug candidates

Simple selection criteria for drug-like chemical matter

New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays

Wisdom of crowds for synthetic accessibility evaluation

Lessons learnt from assembling screening libraries for drug discovery for neglected diseases

Computer-aided drug design and drug pharmacokinetic prediction: A mini-review

A boiled-egg to predict gastrointestinal absorption and brain penetration of small molecules

Estimating drug solubility in the gastrointestinal tract

Development of a new physics-based internal coordinate mechanics force field and its application to protein loop modeling

Molecular docking: A problem with thousands of degrees of freedom

Rational design of potent anti-COVID-19 main protease drugs: An extensive multi-spectrum in silico approach

Structural probing of HapR to identify potent phytochemicals to control Vibrio cholera through integrated computational approaches

Structure-based virtual screening identifies multiple stable binding sites at the RecA domains of SARS-CoV-2 helicase enzyme

AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

Assisted model building with energy refinement. A general program for modeling molecules and their interactions

Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2

Interaction mechanisms of a melatonergic inhibitor in the melatonin synthesis pathway

Binding free energy based analysis of arsenic (+3 oxidation state) methyltransferase with Sadenosylmethionine

Rapid decomposition and visualisation of protein-ligand binding free energies by residue and by water

A water-swap reaction coordinate for the calculation of absolute protein-ligand binding free energies

Structural basis of specific glucoimidazole and mannoimidazole binding by Os3BGlu7

Computational Screening of Phytochemicals against Munc13-1, a Promising target to treat Alcoholism

Computational screening of phytochemicals against survivin protein: A potent target for cancer

Computational screening of medicinal plant phytochemicals to discover potent pan-serotype inhibitors against dengue virus

Rational drug discovery of HCV helicase inhibitor: Improved docking accuracy with multiple seedings of Autodock Vina and in situ minimization

Docking and in silico toxicity assessment of Arthrospira compounds as potential antiviral agents against SARS-CoV-2

Docking study of flavonoid derivatives as potent inhibitors of influenza H1N1 virus neuraminidase

Hydrogen bonding penalty upon ligand binding

Ul-Haq, Z. Pharmacophore model-based virtual screening, docking, biological evaluation and molecular dynamics simulations for inhibitors discovery against α-tryptophan synthase from Mycobacterium tuberculosis

Structure-based virtual screening, free energy of binding and molecular dynamics simulations to propose novel inhibitors of Mtb-MurB oxidoreductase enzyme

In search of SARS CoV-2 replication inhibitors: Virtual screening, molecular dynamics simulations and ADMET analysis

Binding free-energy calculation is a powerful tool for drug optimization: Calculation and measurement of binding free energy for 7-azaindole derivatives to glycogen synthase kinase-3β

Interaction entropy: A new paradigm for highly efficient and reliable computation of protein-ligand binding free energy

In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors

Virtual screening of eighteen million compounds against dengue virus: Combined molecular docking and molecular dynamics simulations study

Camps, I. Potential novel inhibitors against emerging zoonotic pathogen Nipah virus: A virtual screening and molecular dynamics approach

A single dose investigational subunit vaccine for human use against Nipah virus and Hendra virus

Immunoinformatics Approach to design T-cell epitope-based vaccine against hendra virus

Immunoinformatics aided-design of novel multi-epitope based peptide vaccine against Hendra henipavirus through proteome exploration

Combined chloroquine and ribavirin treatment does not prevent death in a hamster model of Nipah and Hendra virus infection

The authors declare no conflict of interest.Molecules 2022, 27, 554